Combining new cancer drugs to treat resistant ovarian cancer
Evaluation of combination CLK/DYRK (Cirtuvivint) inhibition with PARP inhibition (Olaparib) in BRCA/HRD platinum resistant ovarian cancer
This study is looking at how a new drug called cirtuvivint works with an existing treatment, olaparib, to help patients with platinum-resistant ovarian cancer who have certain genetic mutations, hoping to improve their treatment results and health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10852678 on NIH RePORTER |
What this research studies
This research investigates the use of a new drug, cirtuvivint, in combination with an existing treatment, olaparib, for patients with platinum-resistant ovarian cancer. The study focuses on patients who have specific genetic mutations (BRCA1/2) or deficiencies in DNA repair mechanisms. By exploring how these drugs work together, the research aims to overcome resistance to current therapies and improve treatment outcomes. Patients may be monitored for changes in tumor response and overall health as part of the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with platinum-resistant ovarian cancer who have BRCA1/2 mutations or homologous recombination deficiencies.
Not a fit: Patients with ovarian cancer who are not resistant to platinum-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new effective treatment option for patients with resistant ovarian cancer.
How similar studies have performed: Other research has shown promising results with similar combination therapies in overcoming drug resistance in cancer treatment.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Corr, Bradley — University of Colorado Denver
- Study coordinator: Corr, Bradley
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.